Novartis AG
NYSE:NVS · New York Stock Exchange
-$3.38 today
Vol 1.67M · Avg 1.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.5%
avg 21.0%
ROIC
15.5%
avg 9.0%
ROA
12.2%
avg 10.2%
Analysis
ROE is currently the strongest return metric at 30.5% versus its period average of 21.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vasant Narasimhan | Chief Executive Officer | $9.53M | — | 50 | — | — |
Victor Bulto | President of US | $4.21M | — | 48 | — | — |
Mukul Mehta | Chief Financial Officer | $3.77M | — | 53 | — | — |
Patrick Horber | President of International | $3.44M | — | 56 | — | — |
Karen L. Hale | Chief Legal & Compliance Officer | $2.70M | — | 58 | — | — |
Steffen Lang | President of Operations | $2.69M | — | 59 | — | — |
Robert Kowalski | Chief People & Organization Officer | $2.42M | — | 58 | — | — |
Sloan Simpson | Global Head of Investor Relations | — | — | — | — | — |
Paul Penepent | Head of Group Financial Reporting and Accounting | — | — | — | — | — |
Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +23.3% | +3.9% (15yr)5 analysts |
| Revenue | N/A | N/A | -1.0% | +2.2% (15yr)6 analysts |
| Net Income | N/A | N/A | +24.3% | +2.4% (15yr)6 analysts |
| EBIT | N/A | N/A | -7.9% | +6.2% (15yr)6 analysts |
Analysis
Recent growth has been strongest in Net Income at +24.3% over three years. Forward estimates point to EBIT at +6.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.04T
Johnson & Johnson
NYSE:JNJ
$552.00B
AbbVie Inc.
NYSE:ABBV
$382.43B
Roche Holding AG
RHHBY
$320.68B
Merck & Co., Inc.
NYSE:MRK
$281.88B
AstraZeneca PLC
NYSE:AZN
$271.19B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.51B
Pfizer Inc.
NYSE:PFE
$143.80B
Bristol-Myers Squibb Company
NYSE:BMY
$110.07B
GSK plc
NYSE:GSK
$101.97B
Sanofi
NASDAQ:SNY
$101.45B
Bayer AG
BAYRY
$41.62B
Who manages NVS?
Novartis AG (NVS) lists 10 active executives. The top listed executive is Sloan Simpson, Global Head of Investor Relations.
Explore More
Continue the stock analysis
Jump to another research area for this company.